Zobrazeno 1 - 10
of 14
pro vyhledávání: ''
Publikováno v:
Cancer Research. 80:1285-1285
[Introduction] Ovarian cancer is one of the most lethal gynecologic malignancies. More than half of the patients are diagnosed in advanced stages of disease where the prognosis is poor due to the inevitable acquired resistance to platinum agents. Alt
Autor:
Pooja Mehta, Geeta Mehta, Manish S. Patankar, Susan M. Paskewitz, Mayur K. Kajla, Arvinder Kapur
Publikováno v:
Clinical Cancer Research. 25:NT-096
Ovarian cancer is the fifth most common cause of cancer-related deaths in women in the United States. Most women with ovarian cancer present with advanced disease. Even though initial response to surgery and chemotherapy is generally positive, many p
Autor:
Garam Han, Amaro Weiner-Taylor, David Liu, R. Katherine Alpaugh, Elizabeth R. Plimack, Eliezer M. Van Allen, Scott L. Carter, Jean H. Hoffman-Censits, Jaegil Kim, Essel Dulaimi, Gopa Iyer, Kent W. Mouw, Brendan Reardon, Jonathan E. Rosenberg, Daniel Keliher, Min Yuen Teo, Catharine Kline Cipolla, Diana Miao, Stephanie A. Wankowicz, David Y.T. Chen, Levi A. Garraway, Philip Abbosh, Hikmat Al-Ahmadie, Joaquim Bellmunt, Gad Getz
Publikováno v:
Cancer Research. 79:SY05-03
Approximately 20,000 new cases of muscle-invasive bladder cancer (MIBC), a localized but potentially lethal stage of disease, are diagnosed annually in the US alone. Standard-of-care therapy for MIBC includes neoadjuvant cisplatin-based chemotherapy
Autor:
Sean A. Beausoleil, Michael Milhollen, Stephen J. Blakemore, Anthony Possemato, Claudia M. Espitia, Pete Smith, Michael P. Thomas, Allison Berger, Steffan T. Nawrocki, Kevin R. Kelly, Jennifer S. Carew
Publikováno v:
Clinical Cancer Research. 19:3577-3590
Purpose: Ovarian cancer has the highest mortality rate of all female reproductive malignancies. Drug resistance is a major cause of treatment failure and novel therapeutic strategies are urgently needed. MLN4924 is a NEDDylation inhibitor currently u
Autor:
Nicole Urban, Wataru Sakai, Kaitlyn Wurz, Toshiyasu Taniguchi, Beth Y. Karlan, Elizabeth M. Swisher
Publikováno v:
Cancer Research. 68:2581-2586
Although ovarian carcinomas with mutated BRCA1 or BRCA2 are sensitive to platinum compounds, such carcinomas eventually develop platinum resistance. Previously, we showed that acquired resistance to cisplatin in BRCA2-mutated tumors can be mediated b
Autor:
Sandra Orsulic, Deyin Xing
Publikováno v:
Cancer Research. 66:8949-8953
Little is known about the mechanisms that underlie Brca1-associated ovarian tumorigenesis, mainly due to the lack of an appropriate experimental model. We developed genetically defined primary mouse ovarian surface epithelial (OSE) cell lines in whic
Autor:
Roman Fischer, James Chettle, Laki Buluwela, Marie-Laëtitia Thézénas, Manuela Mura, Benedikt M. Kessler, Sarah P. Blagden, Chara Stavraka, Sadaf Ghaem Maghami
Publikováno v:
Cancer Research. 77:B44-B44
Ovarian cancer (OC) is the most lethal gynecological malignancy accounting for 152,000 deaths annually worldwide. Due to the lack of a validated diagnostic tool, patients usually present with disseminated disease and the majority will develop resista
Autor:
Glenn McCluggage, Nuala McCabe, Alistair R.W. Williams, Niamh McGivern, Caroline O. Michie, Laura Hill, Andrena McGavigan, Michael Churchman, Charlie Gourley, Richard D. Kennedy, Karen Keating, Eamonn J. O'Brien, Denis Paul Harkin, Timothy Davison
Publikováno v:
Cancer Research. 76:453-453
Introduction We have previously defined 3 molecular subgroups of High grade serous ovarian cancer (HGSOC), ‘Angio’, ‘Immune’ and ‘Angio_immune’ subgroups using gene expression data from 265 FFPE HGSOC samples obtained from treatment naive
Autor:
Marina Pasca di Magliano, Yunjung Choi, Benjamin L. Allen, Ronald J. Buckanovich, Lan G. Coffman, Karen McLean
Publikováno v:
Clinical Cancer Research. 22:B60-B60
The ovarian tumor microenvironment is critical to ovarian cancer growth, spread, and survival. We recently identified a novel host cell component of the tumor microenvironment, human ovarian carcinoma-associated mesenchymal stem cells (CA-MSCs). CA-M
Publikováno v:
Clinical Cancer Research. 22:B75-B75
Ovarian cancer (OvCa) is the 5th leading cause of cancer-related mortalities among women in the US. The majority of patients diagnosed with OvCa are initially responsive to first-line chemotherapy; however, 75% will suffer a recurrence characterized